170 related articles for article (PubMed ID: 36977840)
1. Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies.
Dhillon S; Duarte-Bateman D; Fowler G; Hagstrom MNE; Lampley N; Olivares S; Fumero-Velázquez MS; Vu K; Wayne JD; Gastman BR; Vetto J; Gerami P
Arch Dermatol Res; 2023 Oct; 315(8):2295-2302. PubMed ID: 36977840
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
[TBL] [Abstract][Full Text] [Related]
3. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R
Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843
[TBL] [Abstract][Full Text] [Related]
4. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK
JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161
[TBL] [Abstract][Full Text] [Related]
5. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
6. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
[TBL] [Abstract][Full Text] [Related]
7. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
[TBL] [Abstract][Full Text] [Related]
8. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.
Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM
Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959
[TBL] [Abstract][Full Text] [Related]
9. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
[TBL] [Abstract][Full Text] [Related]
10. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
11. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
[TBL] [Abstract][Full Text] [Related]
12. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
[TBL] [Abstract][Full Text] [Related]
13. Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients.
Faut M; Wevers KP; van Ginkel RJ; Diercks GF; Hoekstra HJ; Kruijff S; Been LB; van Leeuwen BL
Ann Surg Oncol; 2017 Jan; 24(1):142-149. PubMed ID: 27646020
[TBL] [Abstract][Full Text] [Related]
14. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
Scott AM; Dale PS; Conforti A; Gibbs JN
Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.
Gerami P; Cook RW; Russell MC; Wilkinson J; Amaria RN; Gonzalez R; Lyle S; Jackson GL; Greisinger AJ; Johnson CE; Oelschlager KM; Stone JF; Maetzold DJ; Ferris LK; Wayne JD; Cooper C; Obregon R; Delman KA; Lawson D
J Am Acad Dermatol; 2015 May; 72(5):780-5.e3. PubMed ID: 25748297
[TBL] [Abstract][Full Text] [Related]
16. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma.
Jarell A; Skenderis B; Dillon LD; Dillon K; Martin B; Quick AP; Siegel JJ; Rackley BB; Cook RW
Future Oncol; 2021 Dec; 17(36):5023-5031. PubMed ID: 34587770
[TBL] [Abstract][Full Text] [Related]
17. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy.
Dalal KM; Patel A; Brady MS; Jaques DP; Coit DG
Ann Surg Oncol; 2007 Jun; 14(6):1934-42. PubMed ID: 17406951
[TBL] [Abstract][Full Text] [Related]
18. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy in malignant melanoma of the head and neck.
Rahimi-Nedjat RK; Al-Nawas B; Tuettenberg A; Sagheb K; Grabbe S; Walter C
J Craniomaxillofac Surg; 2018 Jun; 46(6):1027-1031. PubMed ID: 29735384
[TBL] [Abstract][Full Text] [Related]
20. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy.
Moore Dalal K; Zhou Q; Panageas KS; Brady MS; Jaques DP; Coit DG
Ann Surg Oncol; 2008 Aug; 15(8):2206-14. PubMed ID: 18512102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]